Back
 IJMPCERO  Vol.5 No.1 , February 2016
Lung SBRT through Radiobiology
Abstract: Purpose: Stereotactic body radiation therapy (SBRT) has emerged as a standard treatment modality for medically inoperable early-stage lung cancer patients. The aim of this paper is to calculate radiobiological parameters for a sample of 39 patients who underwent lung SBRT. Materials and Methods: For SBRT, a typical regimen of 50 Gy in 4 - 5 fractions results in local tumor control rates around 99.9%. We calculate dose volume histograms (DVHs) of targeted tumors and organs at risk for 39 patients. All patients received 4D imaging, and their internal treatment volumes (ITVs) were created by phase-based sorting of multiple CT datasets. Planning target volume (PTV) diameters ranged from 2.0 to 5.7 cm. The DVHs for the PTV and organs at risk were analyzed using a Biosuite algorithm to calculate the equivalent uniform dose (EUD), tumor control probability (TCP) via a Poisson model, and normal tissue complication probability (NTCP) via an LKB model. The radiobiological effects were analyzed by correlating EUD and TCP with PTV volumes. Results: The mean PTV volume was 31.60 ± 25.55 cc. The mean EUDs were 5.19 ± 2.84, 5.66 ± 4.95, 61.45 ± 29.18, 3.31 ± 5.92, 6.45 ± 5.18, and 12.22 ± 5.94 Gy for lungs, spinal cord, chest/ribs, heart, esophagus, and skin, respectively. On average, the heart had the lowest EUD and the chest/ribs had the highest (61.45 ± 29.18 Gy). The mean NTCPs were estimated at 3.75% ± 2.61%, 36.25% ± 36.42%, and 0.59% ± 1.48%, for the lungs, chest and esophagus, respectively. The NTCPs of spinal cord, heart, and skin were 0.00%. The mean TCP value was 99.72% ± 0.44%. The mean BED value for our study was 109.49 Gy. Conclusions: We have calculated radiobiological predictors based on DVHs for early-stage non-small cell lung cancer via SBRT. Our calculated predictors are compatible with previously published SBRT reports.
Keywords: BED, EUD, NSCLC, NTCP, TCP, SBRT
Cite this paper: Gloi, A. (2016) Lung SBRT through Radiobiology. International Journal of Medical Physics, Clinical Engineering and Radiation Oncology, 5, 78-87. doi: 10.4236/ijmpcero.2016.51008.
References

[1]   Riess, J.W. and Wakelee, H.A. (2012) Metastatic Non-Small Cell Lung Cancer Management: Novel Targets and Recent Clinical Advances. Clinical Advances in Hematology & Oncology, 10, 226-234.

[2]   Kong, F.M., Ten Haken, R.K., Schipper, M.J., Sullivan, M.A., Chen, M., Lopez, C., et al. (2005) High-Dose Radiation Improved Local Control and Overall Survival in Patients with Inoperable/Unresectable Non-Small-Cell Lung Cancer: Long-Term Results of a Radiation Dose Escalation Study. International Journal of Radiation Oncology * Biology * Physics, 63, 324-333.
http://dx.doi.org/10.1016/j.ijrobp.2005.02.010

[3]   Rosenzweig, K.E., Fox, J.L., Yorke, E., Amols, H., Jackson, A., Rusch, V., et al. (2005) Results of a Phase I Dose-Escalation Study Using Three-Dimensional Conformal Radiotherapy in the Treatment of Inoperable Nonsmall Cell Lung Carcinoma. Cancer, 103, 2118-2127.
http://dx.doi.org/10.1002/cncr.21007

[4]   Willner, J., Baier, K., Caragiani, E., Tschammler, A. and Flentje, M. (2002) Dose, Volume, and Tumor Control Predictions in Primary Radiotherapy of Non-Small-Cell Lung Cancer. International Journal of Radiation Oncology * Biology * Physics, 52, 382-389.
http://dx.doi.org/10.1016/S0360-3016(01)01823-5

[5]   Bradley, J., Graham, M.V., Winter, K., Purdy, J.A., Komaki, R. and Roa, W.H. (2005) Toxicity and Outcome Results of RTOG 9311: A Phase I-II Dose-Escalation Study Using Three-Dimensional Conformal Radiotherapy in Patients with Inoperable Non-Small-Cell Lung Carcinoma. International Journal of Radiation Oncology * Biology * Physics, 61, 318-328.
http://dx.doi.org/10.1016/j.ijrobp.2004.06.260

[6]   Timmerman, R., Paulus, R., Galvin, J., Michalski, J., Straube, W., Bradley, J., Fakiris, A., Bezjak, A., Videtic, G., Johnstone, D., Fowler, J., Gore, E. and Choy, H. (2010) Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer. JAMA, 303, 1070-1076.
http://dx.doi.org/10.1001/jama.2010.261

[7]   Barzi, A. and Pennell, N.A. (2010) Targeting Angiogenesis in Non-Small Cell Lung Cancer: Agents in Practice and Clinical Development. EJCMO, 2, 31-42.

[8]   Feng, F.K., Zhao, J., Wang, J. and Faivre, F.C. (2014) Radiation Dose Effect in Locally Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Disease, 6, 336-347.

[9]   Mehta, N., King, C.R., Agazaryan, N., Steinberg, M., Hua, A. and Lee, P. (2012) Stereotactic Body Radiation Therapy and 3-Dimensional Conformal Radiotherapy for Stage I Non-Small Cell Lung Cancer: A Pooled Analysis of Biological Equivalent Dose and Local Control. Practical Radiation Oncology, 2, 288-295.
http://dx.doi.org/10.1016/j.prro.2011.10.004

[10]   Papiez, L. and Timmerman, R. (2008) Hypofractionation in Radiation Therapy and Its Impact. Journal of Medical Physics, 35, 112-118.
http://dx.doi.org/10.1118/1.2816228

[11]   Chang, B.K. and Timmerman, R.D. (2007) Stereotactic Body Radiation Therapy: A Comprehensive Review. Journal of Clinical Oncology, 30, 637-644.
http://dx.doi.org/10.1097/COC.0b013e3180ca7cb1

[12]   Ding, M., Kavanagh, B.D. and Schefter, T. (2005) The Influence of Heterogeneity on Tumor and Normal Lung Dosimetry in Stereotactic Body Radiation Therapy for Lung Cancer Treatment. International Journal of Radiation Oncology * Biology * Physics, 63, S511-S512.
http://dx.doi.org/10.1016/j.ijrobp.2005.07.867

[13]   Herman, T.L., Gabrish, H. and Herman, T.S. (2010) Impact of Tissue Heterogeneity Corrections in Stereotactic Body Radiation Therapy Treatment Plans for Lung Cancer. Journal of Medical Physics, 35, 170-173.
http://dx.doi.org/10.4103/0971-6203.62133

[14]   Timmerman, R.D., Park, C. and Kavanagh, B.C. (2007) The North American Experience with Stereotactic Body Radiation Therapy in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2, 101-112.

[15]   Xiao, Y., Papiez, L. and Paulus, R. (2009) Dosimetric Evaluation of Heterogeneity Corrections for RTOG 0236: Stereotactic Body Radiotherapy of Inoperable Stage I-II Non-Small Cell Lung Cancer. International Journal of Radiation Oncology * Biology * Physics, 73, 1235-1242.
http://dx.doi.org/10.1016/j.ijrobp.2008.11.019

[16]   Takeda, A., Sanuki, N. and Kunieda, E. (2009) Stereotactic Body Radiotherapy for Primary Lung Cancer at a Dose of 50 Gy Total in Five Fractions to the Periphery of the Planning Target Volume Calculated Using a Superposition Algorithm. International Journal of Radiation Oncology *Biology* Physics, 73, 442-448.
http://dx.doi.org/10.1016/j.ijrobp.2008.04.043

[17]   Takahashi, W., Yamashita, H. and Saotome, N. (2012) Evaluation of Heterogeneity Dose Distributions for Stereotactic Radiotherapy (SRT): Comparison of Commercially Available Monte Carlo Dose Calculation with Other Algorithms. Journal of Radiation Oncology, 7, 20.
http://dx.doi.org/10.1186/1748-717X-7-20

[18]   Onishi, H., Nagata, Y., Shirato, H., Arimoto, T., Gomi, K., Karasawa, K., Hayakawa, K., Takai, Y., Ouchi, A. and Takeda, A. (2007) Stereotactic Body Radiotherapy (SBRT, BED ≥ 100 Gy) for Operable Stage I Non-Small Cell Lung Cancer: Is SBRT Comparable to Surgery? International Journal of Radiation Oncology *Biology* Physics, 69, S86-S87.

[19]   Park, S., Urm, S. and Cho, H. (2014) Analysis of Biologically Equivalent Dose of Stereotactic Body Radiotherapy for Primary and Metastatic Lung Tumors. Cancer Research and Treatment, 46, 403-410.
http://dx.doi.org/10.4143/crt.2013.168

[20]   Kong, F.-M., Zhao, J. and Wang, J.B. (2014) Corrine Faivre-Finn: Radiation Dose Effect in Locally Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Disease, 6, 336-347.

[21]   Glide-Hurst, C.K., Smith, M.S., Ajlouni, M. and Chetty, I.J. (2013) Evaluation of Two Synchronized External Surrogates for 4D CT. Journal of Applied Clinical Medical Physics, 14, 4301.

[22]   Uzan, J. and Nahum, A.E. (2012) Radiobiologically Guided Optimization of the Prescription Dose and Fractionation Scheme in Radiotherapy Using BioSuite. The British Journal of Radiology, 85, 1279-1286.
http://dx.doi.org/10.1259/bjr/20476567

[23]   Niemierko, A. (1997) Reporting and Analyzing Dose Distributions: A Concept of Equivalent Uniform Dose. Medical Physics, 24, 103-110.
http://dx.doi.org/10.1118/1.598063

[24]   Gay, H.A. and Niemierko, A. (2007) A Free Program for Calculating EUD-Based NTCP and TCP in External Beam Radiotherapy. Medical Physics, 23, 115-125.
http://dx.doi.org/10.1016/j.ejmp.2007.07.001

[25]   Lyman, J.T. (1985) Complication Probability as Assessed from Dose-Volume Histograms. Radiation Research, 8, S13-S19.
http://dx.doi.org/10.2307/3583506

[26]   Lyman, J.T. and Wolbarst, A.B. (1987) Optimization of Radiation Therapy. III. A Method of Assessing Complication Probabilities from Dose-Volume Histograms. International Journal of Radiation Oncology *Biology* Physics, 13, 103-109.
http://dx.doi.org/10.1016/0360-3016(87)90266-5

[27]   Kutcher, G.J. and Burman, C. (1989) Calculation of Complication Probability Factors for Non-Uniform Normal Tissue Irradiation: The Effective Volume Method. International Journal of Radiation Oncology *Biology* Physics, 16, 1623-1630.
http://dx.doi.org/10.1016/0360-3016(89)90972-3

[28]   Wheldon, T.E., Deehan, C., Wheldon, E.G. and Barrett, A. (1998) The Linear-Quadratic Transformation of Dose-Volume Histograms in Fractionated Radiotherapy. Radiotherapy and Oncology, 46, 285-295.
http://dx.doi.org/10.1016/S0167-8140(97)00162-X

[29]   Niemierko, A. (1999) A Generalized Concept of Equivalent Uniform Dose (EUD). Medical Physics, 26, 1100.

[30]   Luxton, G., Keall, P.J. and King, C.R. (2008) A New Formula for Normal Tissue Complication Probability (NTCP) as a Function of Equivalent Uniform Dose (EUD). Physics in Medicine and Biology, 53, 23-36.
http://dx.doi.org/10.1088/0031-9155/53/1/002

[31]   Nahum, A.E. and Sanchez-Nieto, B. (2001) Tumor Control Probability Modelling: Basic Principles and Applications in Treatment Planning. Physica Medica, 17, 13-23.

[32]   Burman, C., Kutcher, G.J., Emami, B. and Goitein, M. (1991) Fitting of Normal Tissue Tolerance Data to an Analytic Function. International Journal of Radiation Oncology *Biology* Physics, 21, 123-135.
http://dx.doi.org/10.1016/0360-3016(91)90172-Z

[33]   Luxton, G., Keall, P.J. and King, C.R. (2008) A New Formula for Normal Tissue Complication Probability (NTCP) as a Function of Equivalent Uniform Dose (EUD). Physics in Medicine and Biology, 53, 23-36.
http://dx.doi.org/10.1088/0031-9155/53/1/002

[34]   Kim, S.S., Song, S.Y., Kwak, J., Ahn, S.D., Kim, J.H. and Lee, J.S. (2013) Clinical Prognostic Factors and Grading System for Rib Fracture Following Stereotactic Body Radiation Therapy (SBRT) in Patients with Peripheral Lung Tumors. Lung Cancer, 79, 161-166.
http://dx.doi.org/10.1016/j.lungcan.2012.10.011

[35]   Uematsu, M., Shioda, A., Suda, A., Fukui, T., Ozeki, Y., Hama, Y., et al. (2001) Computed Tomography-Guided Frameless Stereotactic Radiotherapy for Stage I Nonsmall-Cell Lung Cancer: A 5-Year Experience. International Journal of Radiation Oncology *Biology* Physics, 51, 666-670.
http://dx.doi.org/10.1016/S0360-3016(01)01703-5

[36]   Nambu, A., Onishi, H., Aoki, S., Tominaga, L., Kuriyama, K., Araya, M., Saito, R., Maehata, Y., Komiyama, T., Marino, K., Koshiishi, T., Sawada, E. and Araki, T. (2013) Rib Fracture after Stereotactic Radiotherapy for Primary Lung Cancer: Prevalence, Degree of Clinical Symptoms, and Risk Factors. BMC Cancer, 13, 68.
http://dx.doi.org/10.1186/1471-2407-13-68

[37]   Onishi, H., Shirato, H., Nagata, Y., Hiraoka, M., Fujino, M. and Gomi, K. (2007) Hypofractionated Stereotactic Radiotherapy (Hypo-FXSRT) for Stage I Non-Small Cell Lung Cancer: Updated Results of 257 Patients in a Japanese Multi-Institutional Study. Journal of Thoracic Oncology, 2, S94-S100.
http://dx.doi.org/10.1097/JTO.0b013e318074de34

[38]   Baumann, P., Nyman, J., Lax, I., Friesland, S., Hoyer, M. and Rehn, E.S. (2006) Factors Important for Efficacy of Stereotactic Body Radiotherapy of Medically Inoperable Stage I Lung Cancer: A Retrospective Analysis of Patients Treated in the Nordic Countries. Acta Oncologica, 45, 787-795.
http://dx.doi.org/10.1080/02841860600904862

[39]   Zhang, J., Yang, F., Li, B., Li, H., Liu, J., Huang, W., et al. (2011) Which Is the Optimal Biologically Effective Dose of Stereotactic Body Radiotherapy for Stage I Non-Small-Cell Lung Cancer? A Meta-Analysis. International Journal of Radiation Oncology *Biology* Physics, 81, e305-e316.
http://dx.doi.org/10.1016/j.ijrobp.2011.04.034

[40]   Li, H., Zhong, H., Kim, J., et al. (2011) Investigation of the Interplay Effect between MLC and Lung Tumor Motions Using 4DCT and RPM Profile Data. Medical Physics, 38, 3692-3693.
http://dx.doi.org/10.1118/1.3612838

[41]   Latifi, K., Oliver, J., Baker, R., et al. (2014) Study of 201 Non-Small Cell Lung Cancer Patients Given Stereotactic Ablative Radiation Therapy Shows Local Control Dependence on Dose Calculation Algorithm. International Journal of Radiation Oncology *Biology* Physics, 88, 1108-1113.
http://dx.doi.org/10.1016/j.ijrobp.2013.12.047

[42]   Timmerman, R., McGarry, R., Yiannoutsos, C., et al. (2006) Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early Stage Lung Cancer. Journal of Clinical Oncology, 24, 4833-4839.
http://dx.doi.org/10.1200/JCO.2006.07.5937

[43]   Timmerman, R.D., Kavanagh, B.D., Cho, L.C., Papiez, L. and Xing, L. (2007) Stereotactic Body Radiation Therapy in Multiple Organ Sites. Journal of Clinical Oncology, 25, 947-952.
http://dx.doi.org/10.1200/JCO.2006.09.7469

[44]   Park, C., Papiez, L., Zhang, S., Story, M. and Timmerman, R.D. (2008) Universal Survival Curve and Single Fraction Equivalent Dose: Useful Tools in Understanding Potency of Ablative Radiotherapy. International Journal of Radiation Oncology *Biology* Physics, 70, 847-852.
http://dx.doi.org/10.1016/j.ijrobp.2007.10.059

 
 
Top